Recent News

• 10.09.2026 - CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
• 10.22.2025 - CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
• 10.14.2025 - CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
• 10.02.2025 - CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
• 08.28.2025 - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
• 08.19.2025 - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
• 07.21.2025 - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
• 06.25.2025 - Breakthroughs in CAR T-Cell Therapies Show Promise for Solid Tumor Cancers
• 06.12.2025 - Saving Time, Saving Lives: Natural Killer Cells and Cancer Therapy
• 05.27.2025 - Natural Killer Cells Are Revolutionizing Cancer Therapy

Recent Filings

• 09.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2026 - EX-99.1 EX-99.1
• 08.11.2026 - 144 Report of proposed sale of securities
• 07.24.2026 - 4/A Statement of changes in beneficial ownership of securities
• 07.24.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 07.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.26.2026 - 3 Initial statement of beneficial ownership of securities